Format

Send to

Choose Destination
  • Filters activated: Field: Title Word. Clear all
Drug Deliv. 2016 Nov;23(9):3319-3329. Epub 2016 May 5.

Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape.

Author information

1
a Akron Biotech , Boca Raton , FL , USA.

Abstract

Liposomes were the first nanoscale drug to be approved for clinical use in 1995. Since then, the technology has grown considerably, and pioneering recent work in liposome-based delivery systems has brought about remarkable developments with significant clinical implications. This includes long-circulating liposomes, stimuli-responsive liposomes, nebulized liposomes, elastic liposomes for topical, oral and transdermal delivery and covalent lipid-drug complexes for improved drug plasma membrane crossing and targeting to specific organelles. While the regulatory bodies' opinion on liposomes is well-documented, current guidance that address new delivery systems are not. This review describes, in depth, the current state-of-the-art of these new liposomal delivery systems and provides a critical overview of the current regulatory landscape surrounding commercialization efforts of higher-level complexity systems, the expected requirements and the hurdles faced by companies seeking to bring novel liposome-based systems for clinical use to market.

KEYWORDS:

Bioengineering; drug delivery; liposomes; regulatory landscape; synthetic biology

PMID:
27145899
DOI:
10.1080/10717544.2016.1177136
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center